phenyl acetate has been researched along with lamifiban in 74 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (52.70) | 18.2507 |
| 2000's | 33 (44.59) | 29.6817 |
| 2010's | 2 (2.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, F; Nakashima, M; Takiguchi, Y; Wada, K | 1 |
| Baumgartner, HR; Kirchhofer, D; Steiner, B; Tschopp, TB | 1 |
| Carteaux, JP; Roux, S; Steiner, B | 1 |
| Carteaux, JP; Clozel, JP; Falivene, L; Hess, P; Roux, S | 1 |
| Carteaux, JP; Colombo, V; Hadváry, P; Kuhn, H; Roux, S; Tschopp, T | 1 |
| Edmunds, LH; Niewiarowski, S | 1 |
| André, P; Arbeille, B; Bal dit Sollier, C; Caen, JP; Drouet, LO; Drouet, V; Hainaud, P | 1 |
| Alig, L; Beresini, M; Blackburn, B; Bunting, S; Hadváry, P; Knopp, D; Levet-Trafit, B; Lipari, MT; Modi, NB; Müller, M; Müller, MH; Refino, CJ; Schmitt, M; Schönholzer, P; Steiner, B; Weiss, S; Weller, T | 1 |
| Bokslag, M; Boudreault, JR; Delage, F; Diodati, JG; Dupuis, R; Fung, AY; Kells, C; Knudtson, ML; Kouz, S; Marquis, JF; Nasmith, J; Rapold, HJ; Roy, L; Steiner, B; Théroux, P | 1 |
| Brandt, R; Chou, RC; Coassolo, P; Lave, T; Saner, A; Schmitt-Hoffmann, AH | 1 |
| André, P; Bal dit Sollier, C; Caen, JP; Drouet, LO; Garfinkel, LI; Hainaud, P | 1 |
| Verheugt, FW | 1 |
| Fitzgerald, DJ; Murphy, NP; Pratico, D | 2 |
| Carroll, RC; Kouns, WC; Lanza, F; Steiner, B; Wang, XF | 1 |
| Gawaz, M; Neumann, FJ; Schömig, A | 1 |
| Moliterno, DJ; Steinhubl, SR | 1 |
| Rossi, G | 1 |
| Adgey, AA | 2 |
| Ferguson, JJ; Lau, TK | 1 |
| Armstrong, PW; Braunwald, E; Califf, RM; Gibler, WB; Hamm, CW; Maseri, A; Simoons, ML; Van de Werf, F | 1 |
| Brosstad, F; Goggin, T; Lehne, G; Midtvedt, K; Nordal, KP | 1 |
| Fitzgerald, D; Harriott, P; Moran, N; O'Luanaigh, N; Reilly, D; Stephens, G; Walker, B | 1 |
| Becker, BF; Heindl, B; Welsch, U; Zahler, S | 1 |
| Aoki, T; Honda, S; Kurata, Y; Matsuzawa, Y; Seki, J; Shiraga, M; Tomiyama, Y | 1 |
| Kleiman, NS | 1 |
| Alexander, JH; Harrington, RA | 1 |
| Bates, ER | 1 |
| Dooley, M; Goa, KL | 1 |
| Greenbaum, AB; Harrington, RA; Hudson, MP; Ohman, EM | 1 |
| Kaluza, G; Kleiman, NS; Mazur, W | 1 |
| Chanu, B | 1 |
| Phillips, J; Stouffer, GA; Subbarao, VD | 1 |
| White, HD | 1 |
| Moliterno, DJ | 1 |
| Zidar, JP | 1 |
| Burckien, L; Himber, J; Steiner, B | 1 |
| Califf, RM; Lincoff, AM; Topol, EJ | 1 |
| Brown, EB; Frojmovic, MM; Liu, Q; Sloan, SM | 1 |
| Blankenship, JC; Frey, CM; Memon, MA; Menapace, FJ; Wood, GC | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Mak, KH; Moliterno, DJ | 1 |
| Bonnefoy, A; Frojmovic, MM; Hantgan, R; Legrand, C | 1 |
| Bachmann, LM; Golder, S; Kleijnen, J; McDonagh, MS; ter Riet, G | 1 |
| Berkowitz, SD | 1 |
| Goto, S; Handa, M; Ikeda, Y; Murata, M | 1 |
| Arnold, N; Bullens, SL; Bunting, S; Chamberlain, J; Chico, TJ; Crossman, DC; Francis, SE; Gadek, TR; Gunn, J; Horton, M; Knolle, J; Lipari, MT; Peyman, A; Quan, C; Shepherd, L; Stilz, HU | 1 |
| Clemetson, JM; Clemetson, KJ; Dörmann, D; Navdaev, A | 1 |
| Bode, C; Nordt, TK; Peter, K | 1 |
| Armstrong, PW; Califf, RM; Christenson, RH; Harrington, RA; Hasselblad, V; Moliterno, DJ; Newby, LK; Ohman, EM; Pfisterer, M; Topol, EJ; Van De Werf, F; White, HD | 1 |
| Ekdahl, KN; Elgue, G; Hong, J; Larsson, A; Larsson, R; Nilsson, B | 1 |
| Boden, WE; McKay, RG | 1 |
| Carroll, RC; Liu, F; Morris, SA; Wang, XF | 1 |
| Barrabés, JA; Blanco, J; Garcia-Dorado, D; Lidón, RM; Mirabet, M; Pizcueta, P; Puigfel, Y; Ruiz-Meana, M; Soler-Soler, J; Soriano, B | 1 |
| SoRelle, R | 1 |
| Berdan, L; Califf, RM; Dyke, C; Gallup, D; Harrington, RA; Lauer, MS; Mahaffey, KW; Mänttäri, M; Moliterno, DJ; Mukherjee, D; Pieper, KS; Roe, MT; Topol, EJ; White, HD; Yadav, JS | 1 |
| Armstrong, PW; Califf, RM; Christenson, RH; Fu, Y; Harrington, RA; Hasselblad, V; Kaul, P; Mahaffey, KW; Newby, LK; Ohman, EM; Topol, EJ; Van de Werf, F | 1 |
| Armstrong, PW; Califf, RM; Fu, Y; Harrington, RA; Hersi, A; Mahaffey, KW; Van de Werf, F; Wong, B | 1 |
| Bhapkar, MV; Califf, RM; Davis, CG; Granger, CB; Harrington, RA; Hochman, JS; Moliterno, DJ; Newby, LK; Simes, RJ; Topol, EJ; Van de Werf, F | 1 |
| Steinhubl, SR | 1 |
| Boersma, E; Westerhout, CM | 2 |
| Dubois, C; Reigner, SC; Riederer, MA; Steiner, B | 1 |
| Arbeille, B; Fauvel-Lafeve, F; Gomes, N; Lebos, C; Legrand, C; Vassy, J | 1 |
| Califf, RM; Crater, SW; Giugliano, RP; Green, CL; Harrington, RA; Johanson, P; Krucoff, MW; Langer, A; Lincoff, AM; Newby, LK; Rebeiz, AG; Roe, MT; Topol, EJ; Wagner, GS | 1 |
| Frojmovic, M; Labarthe, B; Legrand, C | 1 |
| Armstrong, PW; Bolognese, L; Braunwald, E; Califf, RM; Durand, E; Giugliano, RP; Harrington, RA; Hasselblad, V; Kong, DF; Moliterno, DJ; Newby, LK; Prabhakaran, D; Rasoul, S; Stone, GW; Théroux, P; Tricoci, P; Van de Werf, F; White, HD | 1 |
| Karnicki, K; McBane, RD; Wysokinski, WE | 1 |
28 review(s) available for phenyl acetate and lamifiban
| Article | Year |
|---|---|
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine | 1997 |
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 1997 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
New antiplatelet agents for acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1998 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 1998 |
Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Topics: Acetates; Acute Disease; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1998 |
Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Coagulation; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Treatment Outcome; Tyrosine | 1998 |
Lamifiban.
Topics: Acetates; Animals; Bleeding Time; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Tyrosine | 1999 |
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.
Topics: Abciximab; Acetates; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eptifibatide; Fibrinogen; Fibrinolytic Agents; Forecasting; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Pilot Projects; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Tyrosine | 1999 |
Antiplatelet therapy for treatment of acute coronary syndromes.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 1999 |
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
Topics: Acetates; Angina, Unstable; Anticoagulants; Confidence Intervals; Controlled Clinical Trials as Topic; Enoxaparin; Female; Humans; Male; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Survival Rate; Treatment Outcome; Tyrosine | 2000 |
Glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Incidence; Infusions, Intravenous; Intracranial Hemorrhages; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
Topics: Acetates; Acute Disease; Eptifibatide; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tirofiban; Tyrosine | 1999 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
Topics: Acetates; Angina, Unstable; Biphenyl Compounds; Cost-Benefit Analysis; Eptifibatide; Female; Humans; Male; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Pyrrolidines; Tirofiban; Tyrosine | 2000 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
A new approach to antiplatelet therapy: inhibitor of GPIb/V/IX-vWF interaction.
Topics: Acetates; Adenosine Diphosphate; Animals; Antibodies, Monoclonal; Arterial Occlusive Diseases; Collagen; Drug Evaluation, Preclinical; Epinephrine; Epitopes; Genetic Predisposition to Disease; Guinea Pigs; Hemorheology; Humans; Integrins; Liposomes; Macromolecular Substances; Myocardial Infarction; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Polymorphism, Genetic; Receptors, Collagen; Recombinant Fusion Proteins; Stress, Mechanical; Thrombosis; Tyrosine; von Willebrand Factor | 2000 |
[GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Tyrosine | 2001 |
Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.
Topics: Acetates; Clinical Trials as Topic; Electrocardiography; Eptifibatide; Heart Conduction System; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists.
Topics: Acetates; Animals; Blood Coagulation; Blood Platelets; Eptifibatide; Humans; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tyrosine | 2003 |
Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Evaluation; Eptifibatide; Guidelines as Topic; Humans; Immunoglobulin Fab Fragments; Incidence; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2004 |
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Topics: Acetates; Acute Coronary Syndrome; Administration, Cutaneous; Angioplasty; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Tirofiban; Tyrosine | 2011 |
11 trial(s) available for phenyl acetate and lamifiban
| Article | Year |
|---|---|
Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study.
Topics: Acetates; Adult; Aged; Angina, Unstable; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tyrosine | 1996 |
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Gl
Topics: Acetates; Aged; Angina, Unstable; Anticoagulants; Aspirin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Analysis; Tyrosine | 1998 |
Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.
Topics: Acetates; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolysis; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Treatment Outcome; Tyrosine | 1998 |
[Inhibitors of GPIIb/IIIa platelet receptors].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Cerebrovascular Disorders; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 1999 |
Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee.
Topics: Acetates; Adult; Aged; Cohort Studies; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Tyrosine | 2000 |
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Secondary Prevention; Survival Rate; Treatment Outcome; Troponin T; Tyrosine | 2001 |
Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Titrimetry; Treatment Outcome; Tyrosine | 2002 |
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Topics: Acetates; Acute Disease; Aged; Anticoagulants; Coronary Disease; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Tyrosine | 2002 |
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Assessment; Syndrome; Time Factors; Troponin T; Tyrosine | 2003 |
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
Topics: Acetates; Acute Disease; Aged; Arrhythmias, Cardiac; Coronary Disease; Disease-Free Survival; Electrocardiography; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Survival Analysis; Troponin T; Tyrosine | 2003 |
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
Topics: Acetates; Acute Disease; Aged; Aged, 80 and over; Coronary Disease; Female; Heparin; Humans; Infusions, Intravenous; Logistic Models; Male; Middle Aged; Monitoring, Physiologic; Odds Ratio; Partial Thromboplastin Time; Point-of-Care Systems; Syndrome; Tyrosine | 2002 |
35 other study(ies) available for phenyl acetate and lamifiban
| Article | Year |
|---|---|
Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Topics: Acetates; Animals; Biphenyl Compounds; Femoral Artery; Guinea Pigs; Heptanoic Acids; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, Thromboxane; Thrombosis; Thromboxane A2; Tyrosine | 1995 |
Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood.
Topics: Acetates; Anticoagulants; Blood Coagulation; Blood Platelets; Collagen; Enzyme Activation; Factor Xa; Fibrin; Fibrinopeptide A; Hemorheology; Humans; In Vitro Techniques; Macromolecular Substances; Perfusion; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tyrosine | 1995 |
Ro 44-9883, a new non-peptidic GPIIb-GPIIIa antagonist prevents platelet loss in a guinea pig model of extracorporeal circulation.
Topics: Acetates; Adenosine Diphosphate; Amino Acid Sequence; Animals; Extracorporeal Circulation; Guinea Pigs; Hemodynamics; Heparin; Molecular Sequence Data; Oligopeptides; Platelet Aggregation; Platelet Count; Platelet Membrane Glycoproteins; Thrombocytopenia; Tyrosine | 1993 |
Experimental carotid thrombosis in the guinea pig.
Topics: Acetates; Animals; Aspirin; Biomechanical Phenomena; Blood Flow Velocity; Blood Pressure; Carotid Artery Thrombosis; Disease Models, Animal; Guinea Pigs; Heparin; Hirudin Therapy; Male; Partial Thromboplastin Time; Platelet Aggregation; Platelet Count; Tyrosine | 1994 |
Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass.
Topics: Acetates; Animals; Blood Coagulation Tests; Blood Loss, Surgical; Cardiopulmonary Bypass; Dogs; Female; Fibrinogen; Hematocrit; Male; Microscopy, Electron, Scanning; Oxygenators, Membrane; Platelet Aggregation; Platelet Count; Platelet Membrane Glycoproteins; Tyrosine | 1993 |
Fibrinogen receptor antagonists in cardiopulmonary bypass.
Topics: Acetates; Bleeding Time; Cardiopulmonary Bypass; Humans; Platelet Activation; Platelet Membrane Glycoproteins; Tyrosine | 1993 |
Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig.
Topics: Acetates; Animals; Anticoagulants; Capillary Action; Collagen; Fibrin; Guinea Pigs; Humans; In Vitro Techniques; Male; Microscopy, Electron, Scanning; Perfusion; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tyrosine | 1996 |
Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
Topics: Acetates; Administration, Oral; Amidines; Animals; Anticoagulants; Dogs; Macaca mulatta; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Molecular Structure; Oximes; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Rats; Tyrosine | 1996 |
Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor.
Topics: Acetates; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Dogs; Half-Life; Injections, Intravenous; Macaca fascicularis; Male; Platelet Aggregation Inhibitors; Rats; Species Specificity; Spectrophotometry, Ultraviolet; Tyrosine | 1996 |
Relative involvement of GPIb/IX-vWF axis and GPIIb/IIIa in thrombus growth at high shear rates in the guinea pig.
Topics: Acetates; Animals; Anticoagulants; Aurintricarboxylic Acid; Blood Coagulation; Blood Platelets; Guinea Pigs; Hemorheology; Male; Peptide Fragments; Platelet Adhesiveness; Platelet Glycoprotein GPIb-IX Complex; Recombinant Proteins; Tyrosine; von Willebrand Factor | 1997 |
In search of a superaspirin for the heart.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1997 |
Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis.
Topics: Acetates; Animals; Antithrombins; Coronary Vessels; Dogs; Drug Interactions; Naphthalenes; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombin; Thromboxane A2; Tyrosine | 1997 |
Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetates; Adenosine Diphosphate; Blood Platelets; Cytoplasmic Granules; Cytosol; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Lysophospholipids; Peptide Fragments; Phosphorylase a; Phosphorylation; Plasma; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Serotonin; Thrombasthenia; Thromboxane A2; Tyrosine; Vasoconstrictor Agents | 1997 |
[Superaspirin in the platelet aggregation inhibitor therapy].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Integrins; Myocardial Infarction; Oligopeptides; Peptides, Cyclic; Platelet Aggregation Inhibitors; Recurrence; Sulfoxides; Thiazolidines; Time Factors; Tyrosine | 1997 |
Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
Topics: Acetates; Adenosine Diphosphate; Adult; Aged; Bleeding Time; Creatinine; Female; Half-Life; Hematoma; Humans; Kidney Diseases; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Oligopeptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tyrosine | 1998 |
A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis.
Topics: Acetates; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Dual Specificity Phosphatase 2; Fatty Acids, Unsaturated; Flow Cytometry; Humans; Hydrazines; Integrins; Microscopy, Fluorescence; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Signal Transduction; Thromboxane A2; Tyrosine | 1998 |
Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo.
Topics: Acetates; Animals; Binding Sites; Blood Platelets; Coronary Thrombosis; Dogs; Fibrinolytic Agents; Hemorrhage; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Reperfusion Injury; Thromboxane B2; Tissue Plasminogen Activator; Tyrosine | 1998 |
Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts.
Topics: Acetates; Adult; Analysis of Variance; Animals; Blood Platelets; Cell Degranulation; Coronary Vessels; Endothelium, Vascular; Fibrinogen; Guinea Pigs; Humans; Male; Microscopy, Electron; Myocardial Ischemia; Myocardial Reperfusion; Perfusion; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Tyrosine | 1998 |
Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling.
Topics: Acetates; Antibodies, Monoclonal; Benzamidines; Calcium Signaling; Dipeptides; Humans; Intracellular Fluid; Molecular Structure; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Conformation; Structure-Activity Relationship; Tirofiban; Tyrosine; Valerates | 1998 |
Lamifiban.
Topics: Acetates; Animals; Dogs; Guinea Pigs; Haplorhini; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Thrombosis; Tyrosine | 1999 |
Effects of GP IIb/IIIa receptor antagonists on the activating clotting time of heparinized blood.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Blood Coagulation; Hematology; Heparin; Humans; Immunoglobulin Fab Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tyrosine; Whole Blood Coagulation Time | 2000 |
Glycoprotein IIb-IIIa-liposomes bind fibrinogen but do not undergo fibrinogen-mediated aggregation.
Topics: Acetates; Antibodies, Monoclonal; Binding Sites; Blood Platelets; Calcium; Cell Size; Fibrinogen; Flow Cytometry; Humans; Kinetics; Liposomes; Microspheres; Models, Chemical; Particle Size; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Precipitin Tests; Protein Binding; Receptors, Cell Surface; Tyrosine | 2000 |
[New antiplatelet agents].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Dipyridamole; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2000 |
A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor.
Topics: Acetates; Blood Platelets; Fibrinogen; Flow Injection Analysis; Models, Biological; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein Binding; Thrombospondin 1; Thrombospondins; Tyrosine | 2001 |
Effect of selective or combined inhibition of integrins alpha(IIb)beta(3) and alpha(v)beta(3) on thrombosis and neointima after oversized porcine coronary angioplasty.
Topics: Acetates; Angioplasty, Balloon, Coronary; Animals; Cell Adhesion; Disease Models, Animal; Immunohistochemistry; Muscle, Smooth, Vascular; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Vitronectin; Swine; Thrombosis; Tunica Intima; Tyrosine | 2001 |
Echicetin, a GPIb-binding snake C-type lectin from Echis carinatus, also contains a binding site for IgMkappa responsible for platelet agglutination in plasma and inducing signal transduction.
Topics: Acetates; Animals; Aspirin; Avidin; Binding Sites; Biotinylation; Blood Proteins; Carrier Proteins; Chelating Agents; Edetic Acid; Fibrinogen; Immunoglobulin kappa-Chains; Immunoglobulin M; Lectins; Macromolecular Substances; P-Selectin; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proteins; Signal Transduction; Tyrosine; Viper Venoms | 2001 |
Contact between a polymer and whole blood: sequence of events leading to thrombin generation.
Topics: Acetates; Antithrombin III; Erythrocytes; Extracorporeal Circulation; Humans; In Vitro Techniques; Materials Testing; Peptide Hydrolases; Platelet Aggregation; Platelet Aggregation Inhibitors; Polyvinyl Chloride; Thrombin; Tyrosine | 2001 |
Synergistic outside-in regulation of platelet activation by GPIIb/IIIa ligand-induced conformation and oligomerization.
Topics: Acetates; Adenosine Diphosphate; Animals; Antibodies, Monoclonal; Binding Sites; Cricetinae; Cross-Linking Reagents; Dimerization; Drug Synergism; Ligands; Oligopeptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Conformation; Serotonin; Signal Transduction; Thromboxane A2; Tyrosine | 2001 |
Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs.
Topics: Acetates; Animals; Female; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion; Neutrophils; Peroxidase; Platelet Aggregation; Platelet Aggregation Inhibitors; Swine; Tyrosine | 2002 |
Platelet glycoprotein IIb/IIIa inhibitor effect examined in 2 studies.
Topics: Acetates; Acute Disease; Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Syndrome; Treatment Outcome; Tyrosine | 2002 |
Thrombin binding to GPIbalpha induces integrin alphaIIbbeta3 dependent platelet adhesion to fibrin in ex vivo flowing whole blood.
Topics: Acetates; Anticoagulants; Blood; Cell Line, Tumor; Fibrin; Fibrinogen; Humans; Membrane Glycoproteins; Membrane Proteins; Oligopeptides; Peptide Fragments; Perfusion; Platelet Adhesiveness; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Thrombin; Thrombosis; Tyrosine | 2004 |
Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists.
Topics: Abciximab; Acetates; Adenocarcinoma; Antibodies, Monoclonal; Blood Platelets; Blood Vessels; Breast Neoplasms; Cell Adhesion; Endothelium, Vascular; Extracellular Matrix; Female; Humans; Immunoglobulin Fab Fragments; Integrin alphaVbeta3; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Receptors, Vitronectin; Regional Blood Flow; Tumor Cells, Cultured; Tyrosine | 2004 |
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Topics: Abciximab; Acetates; Aged; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Streptokinase; Survival Analysis; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine | 2005 |
Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban.
Topics: Abciximab; Acetates; Adenosine Diphosphate; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Blood Specimen Collection; Fibrinogen; Hemorheology; Humans; Immunoglobulin Fab Fragments; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tyrosine | 2005 |
Platelet recruitment to venous stent thrombi.
Topics: Acetates; Animals; Blood Platelets; Female; Iliac Vein; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Swine; Thrombosis; Tyrosine | 2013 |